# A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

> **NCT00420082** · PHASE2 · COMPLETED · sponsor: **Faes Farma, S.A.** · enrollment: 75 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Bilastine
- **DRUG:** Fexofenadine
- **DRUG:** Cetirizine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00420082
- **Lead sponsor:** Faes Farma, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2012-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420082, "A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00420082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*